13-cisAcitretin
CAS: 69427-46-9
Ref. 3D-FA17201
1mg | Discontinued | ||
2mg | Discontinued | ||
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued |
Product Information
- 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acidisoacitretin13-cis-etretinisoetretinro 13-7652
- (2Z,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
- 13-cis-Acitretin
- 13-cis-Etretin
- 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (2Z,4E,6E,8E)-
- 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (Z,E,E,E)-
- 2,4,6,8-Nonatetraenoicacid,9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-,(Z,E,E,E)-
- A.(2Z,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
- Isoacitretin
- Isoetretin
- See more synonyms
- Ro 13-7652
Acitretin is a synthetic retinoid. It has been shown to be a potent inhibitor of the nuclear receptor co-repressor, which may account for its anti-psoriatic effects. Acitretin is also an active inhibitor of the enzyme squamous cell carcinoma (SCC), which may account for its antitumor activity. Oral administration of acitretin leads to minimal toxicity and increased bioavailability, as well as a high rate constant in humans. This drug has been shown to have minimal toxicity and is more effective than etretinate or acitretin in the treatment of psoriasis, with less side effects such as bowel disease and cancer.